-
A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of DCR-PHXC in Patients With Primary Hyperoxaluria Type 1 or 2 and Severe Renal Impairment With or Without Dialysis
The purpose of this study is to learn whether the study drug DCR-PHXC is safe and able to treat patients with Primary Hyperoxaluria Type 1 ... -
A Phase IIa Open-label Clinical Trial to Evaluate the Safety Pharmacokinetics Pharmacodynamics and Efficacy of BP1001 (a Liposomal Grb2 Antisense Oligonucleotide) in Combination with Venetoclax plus Decitabine in Patients with Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Induction Therapy
The first purpose of this study is to learn if combining the study drug BP1001 with the standard-of-care drugs Venetoclax and decitabine in first line ... -
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1 BRCA2 or PALB2 Mutation
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that ... -
DAY101-001/PNOC026/FIREFLY-1: A Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients with BRAF-Altered Recurrent or Progressive Low-Grade Glioma
The purpose of the study is to evaluate the safety and efficacy of oral pan-RAF inhibitor DAY101 in pediatric, adolescent, and young adult patients with ... -
Fibroblast Growth Factor Regeneration of Tympanic Membrane Perforations
The purpose of this study is to determine if a protein called fibroblast growth factor-2 (FGF-2) can be safely put on the eardrum and help ... -
A Randomized Double-Blinded Placebo-Controlled Study to Evaluate the Safety Tolerability and Efficacy of IMB-1018972 in Patients with Non-obstructive Hypertrophic Cardiomyopathy
This study will examine the effect of IMB-1018972 on exercise capacity and how the heart uses energy. IMB-1018972 is a research drug because it has ... -
A Phase 2 Open-label Multicenter Cohort Study of ALKS 4230 Monotherapy Administered Subcutaneously in Patients With Advanced Cutaneous Melanoma or Intravenously in Patients With Advanced Mucosal Melanoma Who Have Previously Received Anti-PD-[L]1 Therapy - ARTISTRY-6
The purpose of the study is to evaluate the antitumor activity, safety and tolerability of ALKS 4230 given as monotherapy in patients with unresectable and ... -
PH II study of adjuvant tx with cisplatin-based chemotherapy plus concomitant atezolizumab in patients with stage I (tumors > 4cm) IIA IIB and select IIIA [T3N1 T4N0-1] resected NSCLC and the clearance of (ctDNA)
The purpose of the study is to determine and estimate the percentage of patients with undetectable circulating tumor DNA (ctDNA) after 4 cycles of adjuvant ... -
A randomized phase II trial of adjuvant trastuzumab emtansine (T-DM1) followed by subcutaneous trastuzumab versus paclitaxel in combination with subcutaneous trastuzumab for Stage I HER2-positive breast cancer (ATEMPT 2.0)
In stage 1 (early) HER2+ breast cancer, lesser chemotherapy is needed to achieve excellent long-term survival. The current standard therapy is TH (paclitaxel plus trastuzumab ... -
A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop) [EA6192]
The purpose of the study is to evaluate and determine how well biomarkers on PET/CT imaging drive early discontinuation of anti-PD-1 therapy in patients ...